Navigation Links
Human Genome Sciences Appoints John L. Lamattina, Ph.D., to Its Board of Directors
Date:5/8/2008

ROCKVILLE, Md., May 8 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that John L. LaMattina, Ph.D., who retired in late 2007 as President of Pfizer Global Research and Development, has been appointed to the HGS Board of Directors.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )

"We are honored to have John LaMattina join our Board of Directors," said H. Thomas Watkins, President and Chief Executive Officer, HGS. "John's record of accomplishment over the course of a 30-year career at Pfizer has established him as one of the pharmaceutical industry's outstanding worldwide leaders of research and development. In particular, he played an important role in growing Pfizer's pipeline in oncology and guiding its investment in biologics and vaccines. We view the HGS oncology program as a key driver of future growth beyond our late-stage products, and we look forward to benefiting from John's experience and insight as we continue our strategic investment in our pipeline."

As Senior Vice President, Pfizer Inc., and President Pfizer Global Research & Development, Dr. LaMattina led the Pfizer's drug discovery and development efforts in the United States, Europe and Asia. He joined Pfizer in 1977 and over the years held positions of increasing responsibility for Pfizer Central Research, including Vice President of U.S. Discovery Operations, Senior Vice President of Worldwide Discovery Operations and Senior Vice President of Worldwide Development.

Dr. LaMattina graduated cum laude from Boston College, and received his Ph.D. in organic chemistry from the University of New Hampshire, where he worked with Professor Robert E. Lyle. He then moved on to Princeton University as a National Institutes of Health Postdoctoral Fellow in the laboratory of Professor E. C. Taylor. Dr. LaMattina received the 1998 Boston College Alumni Award of Excellence in Science, and received an Honorary Doctor of Science degree from the University of New Hampshire in 2007.

Dr. LaMattina serves on the Board of Directors of the Neurogen Corporation and the Board of Trustees of Boston College.

ABOUT HUMAN GENOME SCIENCES

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.

The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, cancer and other immune-mediated diseases. The Company's primary focus is rapid progress toward the commercialization of its two key lead drugs, Albuferon(R) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. Phase 3 clinical trials of both drugs are ongoing.

ABthrax(TM) (raxibacumab) is in late-stage development for the treatment of inhalation anthrax, and the Company is on track to begin the delivery in fall 2008 of 20,000 doses of ABthrax to the Strategic National Stockpile under a contract entered into with the U.S. Government in June 2006. Other HGS drugs in clinical development include two TRAIL receptor antibodies for the treatment of cancer. HGS1029, a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins, is expected to enter Phase 1 clinical trials soon for the treatment of cancer. In addition, HGS has substantial financial rights to three products in the GlaxoSmithKline clinical development pipeline.

For more information about HGS, please visit the Company's web site at http://www.hgsi.com. Health professionals and patients interested in clinical trials of HGS products may inquire via e-mail to clinical_trials@hgsi.com or by calling HGS at (301) 610-5790, extension 3550.

HGS, Human Genome Sciences, ABthrax, Albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc.

SAFE HARBOR STATEMENT

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with facilities, intense competition, the uncertainty of patent and intellectual property protection, the Company's dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the Company will continue to face risks related to animal and human testing, to the manufacture of ABthrax and to FDA concurrence that ABthrax meets the requirements of the ABthrax contract. If the Company is unable to meet the product requirements associated with the ABthrax contract, the U.S. government will not be required to reimburse the Company for the costs incurred or to purchase any ABthrax doses, and we will not receive any of the expected revenues relative to ABthrax. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.


'/>"/>
SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. St. Jude finds dancing hair cells are key to humans acute hearing
2. Six Youths Secure Top Spots in American Humane Kind Kid Contest
3. AVMA Passes New Policy to Encourage Humane Treatment of Captive Elephants, Appropriate Use of Training Tools
4. Researchers Develop Quick Way to Create Human Antibodies
5. American Humane Forms Human-Animal Bond Division, Including Animal-Assisted Therapy, Humane Ed and Pets & Womens Shelters
6. J. Craig Venter, Human Genome Pioneer, to Receive Award at Vietnam Veterans of Americas National Leadership Conference
7. Jailed Indian Pediatrician Wins 2008 Jonathan Mann Award for Global Health and Human Rights
8. Mutation in human gene helps protect against fatal malaria
9. Scientists Explore Human Gene Pool With Help From Microsoft Research
10. Precyse Solutions Appoints Karen Heisler as New Corporate Vice President, Human Resources
11. European Society of Human Reproduction & Embryology 24th annual meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/25/2017)... ... 25, 2017 , ... FCPX users now have the ability to sharpen a ... ProSharpen Color users have total control over sharpening amount, sharpening radius, threshold, horizontal sharpening, ... spectrum tools users can visually see the color range effected with ease all within ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... its newly designed TaskMate Go. Core benefits and advantages built into the home ... a stylish, functional look and feel. Ability to gain the benefits embedded in ...
(Date:2/24/2017)... ... 2017 , ... Houston dentist , Dr. Behzad Nazari, ... Center. Currently, patients can get single dental implants for $3,599 and All On ... more about these offers by contacting Antoine Dental Center. Both of these options ...
(Date:2/24/2017)... ... February 24, 2017 , ... Only two months after ... Travel Market (ILTM) show in Cannes (France), XO Private has initiated a second print-run ... 420-page book measures almost a metre across when open, weighs in at more than ...
(Date:2/24/2017)... ... February 24, 2017 , ... WHAT: , The New ... opportunities as well as advocacy for the state and region‘s technology businesses, hosted ... The Council's Innovation Forecast event highlights innovation throughout the region from small ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... Feb. 24, 2017  Today, exocad America and ... have a new path to produce 510(K) cleared, ... implant library integrated into exocad DentalCAD software. In ... compliant Good Manufacturing Processes (GMP,s) into their organization, ... and complete an audit process. Then, dental labs can ...
(Date:2/24/2017)... Following receiving CE Marking in Europe ... AMAR is a major milestone for the country where the device was developed ... market in Israel   ... inclusion in the National Health Basket , Israel , ... E-QURE Corp. (OTCQB: EQUR), a leader in medical devices for the treatment of advanced wound ...
(Date:2/24/2017)... Research and Markets has announced the addition of the "Global ... report to their offering. ... The Global Wireless Health Market is poised to ... to reach approximately $330.5 billion by 2025. This industry ... segments on global as well as regional levels presented in the ...
Breaking Medicine Technology: